Investigational drug · Phase 2
IVMED-85
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myopia, Progressive.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "IVMED-85"
First trial start
2027
Feb 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IVMED-85", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myopia, Progressive
Largest trials
Live from ClinicalTrials.gov: studies naming "IVMED-85" as an intervention, largest first.
- Efficacy of IVMED-85 on Pediatric MyopiaPivotal-lookingNot yet recruiting
iVeena Delivery Systems, Inc.Industry
NCT05761795 · 144 participants (planned) · Start Feb 2027 · Primary completion Feb 2029
Drug: IVMED-85 ophthalmic solution, Low Dose; IVMED-85 ophthalmic solution, High dose and 1 more · For: Myopia, Progressive
iVeena Delivery Systems, Inc.Industry
NCT07370584 · 36 participants · Start Feb 4, 2026 · Primary completion Apr 1, 2026
Drug: IVMED-85 ophthalmic solution; Vehicle Ophthalmic Solution · For: Safety Study
Sites: Memphis, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myopia, Progressive
- SHJ002Phase 22 trials
Sunhawk Vision Biotech, Inc. · Myopia, Progressive, Corneal Erosion
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.